WO 2016/179306 Al 10 November 2016 (10.11.2016) P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2016/179306 Al 10 November 2016 (10.11.2016) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/179306 Al 10 November 2016 (10.11.2016) P O P C T (51) International Patent Classification: 358508 (SG). RASHID, Masturah Mohd Abdul; BLK A61K 31/706 (2006.01) A61K 31/573 (2006.01) 456, Hougang Ave. 10, #04-445, Singapore 530456 (SG). A61K 31/407 (2006.01) A61K 31/404 (2006.01) (74) Agents: LIU, Cliff Z. et al; Foley & Lardner LLP, 3000 K A61K 31/69 (2006.01) A61P 35/00 (2006.01) Street N.W., Suite 600, Washington, District of Columbia A61K 31/13 (2006.01) 20007-5 109 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 16/0308 19 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 4 May 2016 (04.05.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/157,348 5 May 2015 (05.05.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicants: THE REGENTS OF THE UNIVERSITY TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. OF CALIFORNIA [US/US]; 1111 Franklin Street, (84) Designated States (unless otherwise indicated, for every Twelfth Floor, Oakland, California 94607-5200 (US). NA¬ kind of regional protection available): ARIPO (BW, GH, TIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 2 1 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Lower Kent Ridge Road, Singapore 119077 (SG). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: HO, Dean; 11826 Dorothy Street, #101, Los TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Angeles, California 90049 (US). HO, Chin-Ming; 11959 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Mayfield Ave., #5, Los Angeles, California 90049 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, VITE, Aleidy Marlene Silva; 10588 Ashton Avenue, Los GW, KM, ML, MR, NE, SN, TD, TG). Angeles, California 90024 (US). ZHANG, Kangyi; 1390 Veteran Ave., #4, Los Angeles, California 90024 (US). Declarations under Rule 4.17 : CHOW, Edward Kai-Hua; 119 Clementi Road, Block I — as to applicant's entitlement to apply for and be granted a #09-18, Singapore 129801 (SG). TOH, Tan Boon; BLK patent (Rule 4.1 7(H)) 88, Bedok North Street 4, #02-129, Singapore 460088 (SG). CHNG, Wee Joo; 12 Melrose Drive, Singapore [Continued on next page] (54) Title: IMPROVED DRUG COMBINATIONS FOR DRUG-RESISTANT AND DRUG-SENSITIVE MULTIPLE MYELOMA of drug combinations Data analysis a d optimization In vitro cellular assay Figure 1 (57) Abstract: Disclosed are pharmaceutical compositions and methods of treating multiple myeloma by providing a pharmaceutic - © ally effective amount of each drug in a combination of drugs. w o 2016/179306 Al III II II 111 I Illlll 111 III III 111 I I II 111 Hill 111 llll 111 llll — as to the applicant's entitlement to claim the priority of — before the expiration of the time limit for amending the the earlier application (Rule 4.17(Hi)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Published: IMPROVED DRUG COMBINATIONS FOR DRUG-RESISTANT AND DRUG- SENSITIVE MULTIPLE MYELOMA Cross-Reference to Related Application [0001] This application claims the benefit of U.S. Provisional Application No. 62/157,348, filed on May 5, 2015, the disclosure of which is incorporated herein by reference in its entirety. Technical Field [0002] This disclosure generally relates to multi-drug therapies for multiple myeloma. Background [0003] The use of drug combinations possesses an important advantage over single drug therapy. Monotherapies often lead to disease recurrence and subsequent ineffectiveness of standard treatment due to drug resistance development. Multi-drug therapies are now the standard treatment for multiple diseases, but their development has involved arduous empirical testing. The design of such therapies is quite challenging since the interactions between drugs are not well understood, as the crossover between the affected cellular pathways is quite difficult to comprehend. Furthermore, combining several drugs at different possible concentrations or dosages yields a large testing parametric space, which makes the search of an optimal combination a major challenge. Therefore, there is a need to use a different approach to develop multi-drug therapies. [0004] It is against this background that a need arose to develop the embodiments described in this disclosure. Summary of Disclosure [0005] In certain aspects, some embodiments of this disclosure are directed to a pharmaceutical composition comprising a pharmaceutically effective amount of each drug in a drug combination selected from the group consisting of: decitabine and mitomycin C; bortezomib and mechlorethamine hydrochloride; decitabine and mechlorethamine hydrochloride; decitabine, mechlorethamine hydrochloride, and mitomycin C; bortezomib, decitabine, and mitomycin C; bortezomib, mechlorethamine hydrochloride, and decitabine; and bortezomib, mechlorethamine hydrochloride, decitabine, and mitomycin C. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of decitabine and mitomycin C. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib and mechlorethamine hydrochloride. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of decitabine and mechlorethamine hydrochloride. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of decitabine, mechlorethamine hydrochloride, and mitomycin C. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, decitabine, and mitomycin C. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, mechlorethamine hydrochloride, and decitabine. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, mechlorethamine hydrochloride, decitabine, and mitomycin C. In some embodiments, the pharmaceutically effective amount, or dosage, of each respective drug in the drug combination is below a maximum tolerated dosage of that respective drug. In some embodiments, the pharmaceutical composition consists essentially of, or consists of, the drug combination. In some embodiments, the pharmaceutical composition comprises, or alternatively consists essentially of, or yet further consists of the drug combination and a pharmaceutical acceptable carrier or excipient. [0006] In other aspects, some embodiments of this disclosure are directed to a pharmaceutical composition comprising a pharmaceutically effective amount of each drug in a drug combination selected from the group consisting of: bortezomib and dexamethasone; bortezomib, panobinostat, and dexamethasone; bortezomib, mechloroethamine hydrochloride, and dexamethasone; and bortezomib, mechloroethamine hydrochloride, panobinostat, and dexamethasone. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib and dexamethasone. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, panobinostat, and dexamethasone. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, mechloroethamine hydrochloride, and dexamethasone. In some embodiments, the drug combination comprises, or alternatively consists essentially of, or yet further consists of bortezomib, mechloroethamine hydrochloride, panobinostat, and dexamethasone. In some embodiments, the pharmaceutically effective amount, or dosage, of each respective drug in the drug combination is below a maximum tolerated dosage of that respective drug. In some embodiments, the pharmaceutical composition consists essentially of, or consists of, the drug combination. In some embodiments, the pharmaceutical composition comprises, or alternatively consists essentially of, or yet further consists of the drug combination and a pharmaceutical acceptable carrier or excipient. [0007] In other aspects, some embodiments of this disclosure are directed to a method of treating bortezomib-resistant multiple myeloma in a subject in need thereof, comprising, or alternatively consisting essentially of, or yet further consisting of administering to the subject a pharmaceutically effective amount of each drug in a drug combination selected from the group consisting of: decitabine and mitomycin C; bortezomib and mechlorethamine hydrochloride; decitabine and mechlorethamine hydrochloride; decitabine, mechlorethamine hydrochloride, and mitomycin C; bortezomib, decitabine, and mitomycin C; bortezomib, mechlorethamine hydrochloride,
Recommended publications
  • A Phase II Study of the Novel Proteasome Inhibitor Bortezomib In
    Memorial Sloan-Kettering Cance r Center IRB Protocol IRB#: 05-103 A(14) A Phase II Study of the Novel Proteas ome Inhibitor Bortezomib in Combination with Rituximab, Cyclophosphamide and Prednisone in Patients with Relapsed/Refractory I Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL) MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL Principal Investigator: John Gerecitano, M.D., Ph.D. Co-Principal Carol Portlock, M.D. Investigator(s): IFormerly: A Phase I/II Study of the Nove l Proteasome Inhibitor Bortezomib in Combinati on with Rituximab, Cyclophosphamide and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL) Amended: 07/25/12 Memorial Sloan-Kettering Cance r Center IRB Protocol IRB#: 05-103 A(14) Investigator(s): Paul Hamlin, M.D. Commack, NY Steven B. Horwitz, M.D. Philip Schulman, M.D. Alison Moskowitz, M.D. Stuart Lichtman, M.D Craig H. Moskowitz, M.D. Stefan Berger, M.D. Ariela Noy, M.D. Julie Fasano, M.D. M. Lia Palomba, M.D., Ph.D. John Fiore, M.D. Jonathan Schatz, M.D. Steven Sugarman, M.D David Straus, M.D. Frank Y. Tsai, M.D. Andrew D. Zelenetz, M.D., Ph.D. Matthew Matasar, M.D Rockville Center, NY Mark L. Heaney, M.D., Ph.D. Pamela Drullinksy, M.D Nicole Lamanna, M.D. Arlyn Apollo, M.D. Zoe Goldberg, M.D. Radiology Kenneth Ng, M.D. Otilia Dumitrescu, M.D. Tiffany Troso-Sandoval, M.D. Andrei Holodny, M.D. Sleepy Hollow, NY Nuclear Medicine Philip Caron, M.D. Heiko Schoder, M.D. Michelle Boyar, M.D.
    [Show full text]
  • Cardiac Events During Treatment with Proteasome Inhibitor Therapy for Multiple Myeloma John H
    Chen et al. Cardio-Oncology (2017) 3:4 DOI 10.1186/s40959-017-0023-9 RESEARCH Open Access Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma John H. Chen1*, Daniel J. Lenihan2, Sharon E. Phillips3, Shelton L. Harrell1 and Robert F. Cornell1 Abstract Background: Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. However, risk factors for cardiac toxicity remain unclear. Our objective was to evaluate the incidence of CAEs associated with PI and recognize risk factors for developing events. Methods: This was a descriptive analysis of 96 patients with multiple myeloma who received bortezomib (n = 44) or carfilzomib (n = 52). We compared the cumulative incidence of CAEs using a log rank test. Patient-related characteristics were assessed and multivariate analysis was used to identify risk factors for developing CAEs. Results: PI-related CAEs occurred in 21 (22%) patients. Bortezomib-associated CAEs occurred in 7 (16%) patients while carfilzomib-associated cardiac events occurred in 14 (27%) patients. The cumulative incidence of CAEs was not significantly different between agents. Events occurred after a median of 67.5 days on PI therapy. Heart failure was the most prevalent event type. More patients receiving carfilzomib were monitored by a cardiologist. By multivariate analysis, a history of prior cardiac events and longer duration of PI therapy were identified as independent risk factors for developing CAEs. Conclusions: AEs were common in patients receiving PIs. Choice of PI did not impact the cumulative incidence of CAEs.
    [Show full text]
  • VELCADE® (Bortezomib) for Injection
    1 VELCADE® (bortezomib) for Injection 2 PRESCRIBING INFORMATION 3 DESCRIPTION 4 VELCADE® (bortezomib) for Injection is an antineoplastic agent available for intravenous 5 injection (IV) use only. Each single dose vial contains 3.5 mg of bortezomib as a sterile 6 lyophilized powder. Inactive ingredient: 35 mg mannitol, USP. 7 Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic 8 ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its 9 hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic 10 anhydride form as a trimeric boroxine. 11 The chemical name for bortezomib, the monomeric boronic acid, is [(1R)-3-methyl-1-[[(2S)-1- 12 oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid. 13 Bortezomib has the following chemical structure: O OH H N N B N OH H O N 14 15 The molecular weight is 384.24. The molecular formula is C19H25BN4O4. The solubility of 16 bortezomib, as the monomeric boronic acid, in water is 3.3 to 3.8 mg/mL in a pH range of 2 to 17 6.5. 18 CLINICAL PHARMACOLOGY 19 Mechanism of Action 20 Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in 21 mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated 22 proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular 23 concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of 24 the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling 25 cascades within the cell.
    [Show full text]
  • Abstract in Vivo Mouse Studies Drug Resistant Myeloma Cell Lines Ex
    Overcoming Drug-resistance in Multiple Myeloma by CRM1 Inhibitor Combination Therapy Joel G. Turner1, Ken Shain1, Yun Dai2, Jana L. Dawson1, Chris Cubitt1, Sharon Shacham3, 1 3 2 1 H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Sharon Shacham , Michael Kaffman , Steven Grant and Daniel M. Sullivan AN NCI COMPREHENSIVE CANCER CENTER – Tampa, FL 1-888-MOFFITT (1-888-663-3488) www.MOFFITT.org 1 Moffitt Cancer Center and Research Institute, Tampa, FL © 2010 H. Lee Moffitt Cancer Center and Research Institute, Inc. 2 Virginia Commonwealth University, Richmond, VA 3 Karyopharm Therapeutics, Natick, MA Abstract Drug Resistant Myeloma Cell Lines In Vivo Mouse Studies Ex vivo Apoptosis Assay Introduction Newly Diagnosed Newly Diagnosed Significant progress has been made over the past several years in the treatment A 70 VC B 70 VC KPT-330 of multiple myeloma (MM). However patients eventually develop drug resistance A B 60 60 KPT-330 KOS-2464 KOS-2464 and die from progressive disease. The incurable nature of MM clearly 50 50 demonstrates the need for novel agents and treatments. 40 40 The overall objective of this study was to investigate the use of CRM1 inhibitors 30 30 Apoptosis (%) Apoptosis (KPT330 and KOS2464) to sensitize de novo and acquired drug-resistant MM (%) Apoptosis 20 20 cells to the proteosome inhibitors bortezomib (BTZ)and carfilzomib (CFZ) and to 10 10 the topoisomerase II (topo II) inhibitor doxorubicin (DOX). 0 0 Methods VC or Drug BTZ CFZ DOX VC or Drug BTZ CFZ DOX Drug resistant U266 and 8226 MM cell lines were developed at VCU (Steven Relapsed Relapsed Grant) and the Moffitt Cancer Center (Ken Shain) respectively by the incremental C 70 VC D 70 VC KPT-330 exposure to BTZ.
    [Show full text]
  • Vorinostat—An Overview Aditya Kumar Bubna
    E-IJD RESIDENTS' PAGE Vorinostat—An Overview Aditya Kumar Bubna Abstract From the Consultant Vorinostat is a new drug used in the management of cutaneous T cell lymphoma when the Dermatologist, Kedar Hospital, disease persists, gets worse or comes back during or after treatment with other medicines. It is Chennai, Tamil Nadu, India an efficacious and well tolerated drug and has been considered a novel drug in the treatment of this condition. Currently apart from cutaneous T cell lymphoma the role of Vorinostat for Address for correspondence: other types of cancers is being investigated both as mono-therapy and combination therapy. Dr. Aditya Kumar Bubna, Kedar Hospital, Mugalivakkam Key Words: Cutaneous T cell lymphoma, histone deacytelase inhibitor, Vorinostat Main Road, Porur, Chennai - 600 125, Tamil Nadu, India. E-mail: [email protected] What was known? • Vorinostat is a histone deacetylase inhibitor. • It is an FDA approved drug for the treatment of cutaneous T cell lymphoma. Introduction of Vorinostat is approximately 9. Vorinostat is slightly Vorinostat is a histone deacetylase (HDAC) inhibitor, soluble in water, alcohol, isopropanol and acetone and is structurally belonging to the hydroxymate group. Other completely soluble in dimethyl sulfoxide. drugs in this group include Givinostat, Abexinostat, Mechanism of action Panobinostat, Belinostat and Trichostatin A. These Vorinostat is a broad inhibitor of HDAC activity and inhibits are an emergency class of drugs with potential anti- class I and class II HDAC enzymes.[2,3] However, Vorinostat neoplastic activity. These drugs were developed with the does not inhibit HDACs belonging to class III. Based on realization that apart from genetic mutation, alteration crystallographic studies, it has been seen that Vorinostat of HDAC enzymes affected the phenotypic and genotypic binds to the zinc atom of the catalytic site of the HDAC expression in cells, which in turn lead to disturbed enzyme with the phenyl ring of Vorinostat projecting out of homeostasis and neoplastic growth.
    [Show full text]
  • FARYDAK (Panobinostat) RATIONALE for INCLUSION in PA PROGRAM
    FARYDAK (panobinostat) RATIONALE FOR INCLUSION IN PA PROGRAM Background Farydak (panobinostat) is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma in patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Farydak is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication. Multiple myeloma causes plasma cells to rapidly multiply and crowd out other healthy blood cells from the bone marrow. When the bone marrow has too many plasma cells, the cells may move to other parts of the body. Farydak works by inhibiting the activity of enzymes, known as histone deacetylases (HDACs). The inhibition of these enzymes may slow the over development of plasma cells in multiple myeloma patients or cause these dangerous cells to die (1). Regulatory Status FDA-approved indication: Farydak, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent (2). Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Arrhythmias may be exacerbated by electrolyte abnormalities. The most common laboratory abnormalities were low levels of phosphorus in the blood (hypophosphatemia), low potassium levels in the blood (hypokalemia), low levels of salt in the blood (hyponatremia), increased creatinine, low platelets (thrombocytopenia), low white blood cell counts (leukopenia) and low red blood cell counts (anemia).
    [Show full text]
  • Combining Milatuzumab with Bortezomib, Doxorubicin, Or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines Rhona Stein,1Mitchell R
    CancerTherapy: Preclinical Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines Rhona Stein,1Mitchell R. Smith,2 Susan Chen,1Maria Zalath,1and David M. Goldenberg1 Abstract Purpose: The humanized anti-CD74 monoclonal antibody, milatuzumab, is in clinical evaluation for the therapy of multiple myeloma (MM). The ability of milatuzumab to increase the efficacy of bortezomib, doxorubicin, and dexamethasone was examined in three human CD74+ MM cell lines, CAG, KMS11, KMS12-PE, and one CD74-MM cell line, OPM-2. Experimental Design: Activity of milatuzumab as a monotherapy and combined with the drugs was evaluated by studying in vitro cytotoxicity, signaling and apoptotic pathways, and in vivo therapeutic activity in severe combined immunodeficient (SCID) mouse models of MM. Results: Given as a monotherapy, cross-linked milatuzumab, but not milatuzumab alone, yielded sig- nificant antiproliferative effects in CD74+ cells.The combination of cross-linked milatuzumab with bortezomib, doxorubicin, or dexamethasone caused more growth inhibition than either cross-linked milatuzumab or drug alone, producing significant reductions in the IC50 of the drugs when combined. Efficacy of combined treatments was accompanied by increased levels of apoptosis measured by increases of activated caspase-3 and hypodiploid DNA. Both milatuzumab and bortezomib affect the nuclear factor-nB pathwayinCAGMMcells. In CAG-or KMS11-SCIDxenograftmodels ofdisseminated MM, milatuzumab more than doubled median survival time, compared withup to a 33% increase in median survival withbortezomib but no significant benefit with doxorubicin. Moreover, combining milatuzumabandbortezomibincreasedsurvivalsignificantlycomparedwitheither treatmentalone. Conclusions:The therapeutic efficacies of bortezomib, doxorubicin, and dexamethasone are en- hanced in MM cell lines when given in combination with milatuzumab, suggesting testing these combinations clinically.
    [Show full text]
  • Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
    ANTICANCER RESEARCH 33: 4475-4482 (2013) Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer AHMAD A. TARHINI1,2, HARIS ZAHOOR1, BRIAN MCLAUGHLIN1, WILLIAM E GOODING2, JOHN C. SCHMITZ2, JILL M. SIEGFRIED2, MARK A. SOCINSKI1,2 and ATHANASSIOS ARGIRIS3 1University of Pittsburgh Medical Center, 2University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, Pittsburgh, PA, U.S.A.; 3University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A. Abstract. A phase I trial consisting of panobinostat (a apoptosis in response to HDAC inhibitors may also be HDAC inhibitor), carboplatin and etoposide was condacted in mediated by acetylation of non-histone proteins (such as patients with lung cancer. Patients and Methods: Patients HSP-90, p53, HIF1-α, α-tubulin) (5). received carboplatin AUC5 on day 1 and etoposide 100 mg/m2 Panobinostat, a hydroxamic acid derivative, is an oral pan- on days 1, 2 and 3, every 21 days. Concurrent oral deacetylase inhibitor (6). It affects proteins involved in cell-cycle panobinostat was given 3 times weekly on a 2-weeks-on and 1- regulation (p53, p21), angiogenesis (HIF-1α), gene transcription week-off schedule during the 4-6 cycles of chemotherapy and (transcription factors), protein stabilization (Hsp90) and then continued as maintenance therapy. Results: Six evaluable cytoskeleton (α-tubulin), through inhibition of HDACs (7, 8). patients were treated at the first dose level of panobinostat Panobinostat exhibits increased histone acetylation and (10 mg). Dose-limiting toxicity occurred in two patients (33%) has potent antiproliferative activity against a broad range of during the first cycle.
    [Show full text]
  • Management of Multiple Myeloma: the Changing Paradigm
    Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives • Discuss use of standard myeloma therapies when used as therapy after relapse • Consider patient and disease factors which might impact therapy decisions. • Describe off-label options for patients who are not protocol candidates. Line ≠ Line ≠ Line ≠ … POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLI LINE – DO NOT Define “Line” • A pre-defined course of therapy utilizing agents either simultaneously or sequentially – Len/Dex – Len/Dex ASCT – Vel/Dex ASCT Len/Dex – VDT-PACE ASCT TD ASCT VPT-PACE LD • Pts who have had the same # of “lines” of Rx may have had vastly different amounts of Rx What Is Relapsed/Refractory Disease? • Relapsed: recurrence after a response to therapy • Refractory: progression despite ongoing therapy What Do We Know About the Pt’s Myeloma? • What prior therapy has been used? • How well did it work? • Did the myeloma progress on active therapy? • High-risk cytogenetics/FISH/GEP? What Do We Know About the Patient? • Age • Other medical problems – Diabetes – Blood Clots • Lasting side effects from past therapies – Peripheral Neuropathy • Personal preferences and values Choosing Therapy for Relapsed/Refractory Myeloma Proteasome IMiDs Anthracyclines Alkylators Steroids HDACs Antibodies Inhibitors Thalidomide Bortezomib Doxil Melphalan Dex Panobinostat Elotuzumab Lenalidomide Carfilzomib Cytoxan Pred Vorinostat
    [Show full text]
  • (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia 2012-1064
    2012-1064 September 02, 2014 Page 1 Protocol Page Phase I/II Study of Decitabine (DAC) followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia 2012-1064 Core Protocol Information Short Title Decitabine followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia Study Chair: Nitin Jain Additional Contact: Allison Pike Jeannice Y. Theriot Leukemia Protocol Review Group Department: Leukemia Phone: 713-745-6080 Unit: 428 Full Title: Phase I/II Study of Decitabine (DAC) followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia Protocol Type: Standard Protocol Protocol Phase: Phase I/Phase II Version Status: Terminated 01/12/2018 Version: 12 Submitted by: Jeannice Y. Theriot--4/26/2017 2:13:38 PM OPR Action: Accepted by: Melinda E. Gordon -- 5/1/2017 7:55:15 AM Which Committee will review this protocol? The Clinical Research Committee - (CRC) 2012-1064 September 02, 2014 Page 2 Protocol Body Phase I/II Study of Decitabine (DAC) followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia 1. OBJECTIVES Phase I Primary: To determine the maximal tolerated dose (MTD) of clofarabine to be used in portion II of the study Phase II Primary: To determine the response rate of the DAC-CIA regimen Secondary: A) To determine the toxicity of the combination regimen B) To determine the disease-free survival (DFS) and overall survival (OS) rates 2. RATIONALE 2.1 Acute Myelogenous Leukemia Acute myelogenous leukemia (AML) is the most common acute leukemia in adults. It is estimated that 13,780 men and women will be diagnosed with and 10,200 men and women will die of acute myeloid leukemia in the year 2012.1 AML is a disease with a poor prognosis with a 5-year survival of only around 30%.2,3 Certain subgroups of AML have a particularly worse Page 1 of 34 outcome such as patients with relapsed and/or refractory AML and AML arising from antecedent myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs).
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Azacytidine Sensitizes Acute Myeloid Leukemia Cells to Arsenic Trioxide By
    Chau et al. Journal of Hematology & Oncology (2015) 8:46 DOI 10.1186/s13045-015-0143-3 JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH ARTICLE Open Access Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9 David Chau1†, Karen Ng1†, Thomas Sau-Yan Chan1, Yuen-Yee Cheng1,3, Bonnie Fong2, Sidney Tam2, Yok-Lam Kwong1 and Eric Tse1* Abstract Background: The therapeutic efficacy of arsenic trioxide (As2O3) in acute myeloid leukemia (AML) is modest, which is partly related to its limited intracellular uptake into the leukemic cells. As2O3 enters cells via the transmembrane protein aquaglyceroporin 9 (AQP9). Azacytidine, a demethylating agent that is approved for the treatment of AML, has been shown to have synergistic effect with As2O3. We tested the hypothesis that azacytidine might up-regulate AQP9 and enhances As2O3-mediated cytotoxicity in AML. Methods: Arsenic-induced cytotoxicity, the expression of AQP9, and the intracellular uptake of As2O3 were determined in AML cell lines and primary AML cells with or without azacytidine pre-treatment. The mechanism of AQP9 up-regulation was then investigated by examining the expression of transcription factors for AQP9 gene and the methylation status of their gene promoters. Results: As2O3-induced cytotoxicity in AML cell lines was significantly enhanced after azacytidine pre-treatment as a result of AQP9 up-regulation, leading to increased arsenic uptake and hence intracellular concentration. Blocking AQP9-mediated As2O3 uptake with mercury chloride abrogated the sensitization effect of azacytidine. AQP9 promoter does not contain CpG islands. Instead, azacytidine pre-treatment led to increased expression of HNF1A, a transcription activator of AQP9, through demethylation of HNF1A promoter.
    [Show full text]